Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec;14(12):1845-1848.
doi: 10.1002/alr.23486. Epub 2024 Nov 5.

Surgery versus biologics for nasal polyposis: Perspective on contemporary data

Michael J Ye  1 , Rodney J Schlosser  2 , Zachary M Soler  2 , Jonathan B Overdevest  3 , David A Gudis  3
Affiliations
Editorial

Surgery versus biologics for nasal polyposis: Perspective on contemporary data

Michael J Ye et al. Int Forum Allergy Rhinol. 2024 Dec.
No abstract available

Keywords: FESS; SNOT‐22; chronic rhinosinusitis; endoscopic sinus surgery; medical therapy of chronic rhinosinusitis; sinus surgery; sinusitis.

PubMed Disclaimer

References

REFERENCES

    1. Miglani A, Soler ZM, Smith TL, Mace JC, Schlosser RJ. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis. Int Forum Allergy Rhinol. 2023;13(2):116‐128. doi:10.1002/alr.23059
    1. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS‐24 and LIBERTY NP SINUS‐52): results from two multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group phase 3 trials. Lancet. 2019;394(10209):1638‐1650. doi:10.1016/S0140‐6736(19)31881‐1. Erratum in: Lancet. 2019 Nov 2;394(10209):1618
    1. Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141‐1153. doi:10.1016/S2213‐2600(21)00097‐7
    1. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595‐605. doi:10.1016/j.jaci.2020.05.032. Erratum in: J Allergy Clin Immunol. 2021 Jan;147(1):416. PMID: 32524991.
    1. Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello‐Petersen R, Chu DK. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta‐analysis. J Allergy Clin Immunol. 2022;149(4):1286‐1295. doi:10.1016/j.jaci.2021.09.009

Publication types

LinkOut - more resources